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Abstract
Insulin resistance, the key defect in type 2 diabetes (T2D), is associated with a low capacity to adapt fuel oxidation to fuel
availability, i.e., metabolic inflexibility. This, in turn, contributes to a further damage of insulin signaling. Effectiveness of T2D
treatment depends in large part on the improvement of insulin sensitivity and metabolic adaptability of the muscle, the
main site of whole-body glucose utilization. We have shown previously in mice fed an obesogenic high-fat diet that a
combined use of n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and thiazolidinediones (TZDs), anti-diabetic
drugs, preserved metabolic health and synergistically improved muscle insulin sensitivity. We investigated here whether n-3
LC-PUFA could elicit additive beneficial effects on metabolic flexibility when combined with a TZD drug rosiglitazone. Adult
male C57BL/6N mice were fed an obesogenic corn oil–based high-fat diet (cHF) for 8 weeks, or randomly assigned to
various interventions: cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids (cHF+F), cHF with 10 mg
rosiglitazone/kg diet (cHF+ROSI), cHF+F+ROSI, or chow-fed. Indirect calorimetry demonstrated superior preservation of
metabolic flexibility to carbohydrates in response to the combined intervention. Metabolomic and gene expression analyses
in the muscle suggested distinct and complementary effects of the interventions, with n-3 LC-PUFA supporting complete
oxidation of fatty acids in mitochondria and the combination with n-3 LC-PUFA and rosiglitazone augmenting insulin
sensitivity by the modulation of branched-chain amino acid metabolism. These beneficial metabolic effects were associated
with the activation of the switch between glycolytic and oxidative muscle fibers, especially in the cHF+F+ROSI mice. Our
results further support the idea that the combined use of n-3 LC-PUFA and TZDs could improve the efficacy of the therapy
of obese and diabetic patients.
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Introduction
Combined treatments with multiple mechanisms of action are
required for a better handling of metabolic diseases associated with
obesity [1–4]. Thus, dietary, lifestyle, and pharmacological
interventions should all be considered in the therapy of patients
with type 2 diabetes (T2D), the major metabolic disease triggered
by obesity [5].
Naturally occurring n-3 long-chain polyunsaturated fatty acids (n-
3 LC-PUFA), namely eicosapentaenoic acid (EPA; 20:5n-3) and
docosahexaenoic acid (DHA; 22:6n-3) are now regarded as healthy
constituents of diets for diabetic patients [6–8]. These lipids, which
are abundant in sea fish, act as hypolipidemics and augment the
efficacy of the lipid-lowering drugs [4], and reduce cardiac events
and decrease progression of atherosclerosis (reviewed in ref.
[7,9,10]). Numerous animal studies demonstrated reduced accu-
mulation of body fat in response to dietary n-3 LC-PUFA
supplementation [11–18], especially when combined with calorie
restriction [19], reflecting possibly reduced proliferation of fat cells
[12,20], and/or metabolic changes in the liver [15,21], adipose
tissue [13,19], and intestine [22]. In contrast, only few randomized
clinical trials demonstrated a reduction of adiposity after n-3 LC-
PUFA supplementation [23–26], while other studies in humans
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could not reveal any anti-obesity effect of n-3 LC-PUFA [27,28].
Moreover, in rodents, n-3 LC-PUFA prevented [14,21,29–31] and
even reversed [14,32] insulin resistance induced by high-fat feeding,
while n-3 LC-PUFA had little effect on glycemic control and insulin
sensitivity in diabetic patients [23,33,34].
Impairment of insulin sensitivity represents the key defect in T2D.
It is associated with a low capacity to adapt fuel oxidation to fuel
availability, i.e., metabolic inflexibility [35,36]. This results in lower
glucose oxidation during insulin-stimulated conditions and in
relatively low activation of lipid catabolism when lipids represent
the main metabolic fuel, which further support accumulation of
ectopic fat and lipotoxicity with a deleterious effect on insulin
signaling [35]. Recent studies based on metabolomics suggest that
both incomplete mitochondrial fatty acid oxidation and abnormal
metabolism of branched-chain amino acids (BCAA) [37,38] could
contribute to insulin resistance, especially in the context of high fat-
feeding in rodents and/or obesity (reviewed in [39]). In turn, this
novel mechanistic insight may help to develop causal and more
effective treatment strategies for T2D patients.
In our previous studies, we sought to learn whether n-3 LC-PUFA
could augment the effects of anti-diabetic drugs, namely thiazoli-
dinediones (TZDs). Thus, using a model of dietary obese mice and
euglycemic-hyperinsulinemic clamps to measure insulin sensitivity,
we have demonstrated that the combined use of n-3 LC-PUFA and
TZD rosiglitazone, both administered at a relatively low dose (a
‘combined intervention’), exerted synergistic effects in prevention as
well as reversal of insulin resistance [14]. These effects reflected a
synergistic improvement in muscle insulin sensitivity [14], depend-
ing possibly in part on the induction of adiponectin [14,32]. The
combined intervention also exerted additivity in the counteraction
of both dyslipidemia [14,32] and low-grade inflammation of adipose
tissue [14]. Also pioglitazone, a TZD used currently in treatment of
diabetic patients [40], prevented both dyslipidemia and impairment
of glucose homeostasis more efficiently in the combination with n-3
LC-PUFA as compared with the single intervention [32]. In
addition, rosiglitazone, at the low dose used [14,32], but not
pioglitazone [32], augmented the anti-obesity effect of n-3 LC-
PUFA. Changes in plasma metabolome suggested that the anti-
obesity effect of the combined intervention reflected induction of
fatty acid b-oxidation [32].
Motivated by our findings revealing synergistic effect of the
combined use of n-3 LC-PUFA and rosiglitazone on muscle insulin
sensitivity in dietary obesemice (refs. [14,32]; see also above), and by
the fact that skeletalmuscle is themain site of glucose uptake [35], we
aimed to verify a hypothesis that improvement of metabolic
flexibility is an important part of the beneficial effects of the
combined intervention. We also sought to learn what are the
mechanisms underlying the improvement of muscle insulin sensi-
tivity in response to the combined intervention. To examine this, we
applied our established treatment protocol to high-fat diet-fed mice
[14,32]. Indirect calorimetry results indicated superior preservation
ofmetabolic flexibility to carbohydrates in response to the combined
intervention. Moreover, metabolomic analysis as well as evaluation
of gene expression in skeletal muscle revealed (i) partially distinct
mechanisms of action of n-3 LC-PUFA and rosiglitazone, and (ii)
additive activation of the switch between glycolytic and oxidative
muscle fibers in response to the combined intervention.
Results
Assessment of Intervention
In agreement with our previous experiments [14,32], when
adult mice (see Fig. 1A) were randomly assigned to an obesogenic
high-fat diet (cHF) or to the following cHF-based diets supple-
mented with (i) n-3 LC-PUFA (cHF+F); (ii) a low dose of
rosiglitazone (cHF+ROSI); and (iii) both n-3 LC-PUFA concen-
trate and rosiglitazone (cHF+F+ROSI), only the combined
intervention prevented development of obesity during 8 weeks of
the high-fat feeding experiment (Table 1). As observed before
[14,32], food consumption was not significantly affected by any of
the interventions (data not shown).
To evaluate plasma parameters at the end of the experiment at
week 8, a ‘diet-switch protocol’ was applied (see Fig 1 and
Methods), similarly as in the case of indirect calorimetry, which
was performed during week 6 (see below). Thus, mice, which were
fed during the whole experiment various cHF-based diets, were
fasted during the light phase of the day and re-fed standard low-fat
(Chow) diet during the night. Plasma was collected and glycemia
was measured in (i) mice with ad libitum access to various cHF-
based diets, before fasting, and (ii) mice re-fed Chow overnight. In
the mice before fasting, the combined intervention strongly
reduced plasma levels of triglycerides, even when compared with
the mice fed Chow diet. Moreover, both n-3 LC-PUFA containing
diets (cHF+F and cHF+F+ROSI) decreased NEFA levels in
plasma (Table 1). Glycemia was not affected by any of the
interventions (Table 1), in spite of the synergistic improvement of
muscle insulin sensitivity in response to the combined intervention
observed already before [14,32]. Feeding cHF diet increased
plasma insulin levels as compared with the Chow mice, while the
combined intervention counteracted this effect (see also refs
[14,32]).
In the animals fasted during the day and re-fed Chow overnight,
the hypolipidemic effects of n-3 LC-PUFA containing diets
disappeared, and insulin levels in all the groups were similar to
the Chow-fed control mice. Glycemia was similar in all the
animals maintained on various cHF-based diets during the
experiment, while insulin levels tended to be lower in the
cHF+F+ROSI as compared with the cHF mice (Table 1). In
addition, the combination intervention prevented cHF-induced
elevation of b-hydroxybutyrate levels in plasma, while the single
interventions had no effect (Table 1).
Assessment of Metabolic Flexibility
During week 6 of the experiment, indirect calorimetry was
performed, using the diet-switch protocol mentioned above, i.e.,
during the course of the subsequent periods of (i) feeding various
cHF-based diets, (ii) fasting, and (iii) re-feeding Chow diet (i.e.,
low-fat diet with a carbohydrate/fat ratio of 16.3, wt/wt, as
compared with the corresponding ratio of 1.0 in the case of the
cHF-based diets; see Methods and ref. [14]). Neither oxygen
consumption (VO2), nor respiratory exchange ratio (RER;
calculated as carbon dioxide production, VCO2, divided by
VO2), the marker of fuel partitioning, were affected by any of the
interventions, except for (i) a slight depression of VO2 in the
cHF+F+ROSI mice during fasting (Table 2), and (ii) an increase in
RER during re-feeding Chow diet in response to all the
interventions. This increase was similar in the cHF and
cHF+ROSI mice (Fig. 2B, Table 2), while the cHF+F mice
exhibited a transiently higher induction during the second half of
the dark phase of the day (Fig. 2B). Mice subjected to the
combined intervention displayed the highest induction, which
prevailed even during the light phase of the day (Fig. 2B). Percent
relative cumulative frequency (PRCF) curves were constructed,
based on RER values pooled from all animals within a given
dietary group. This was done for the fasting and Chow periods
(Fig. 2C). The values of log EC50 of PRCF (50
th percentile value)
correspond to median RER values [41]. This robust approach
confirmed the RER data, indicating a shift from lipid to
n-3 Fatty Acids and Rosiglitazone
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carbohydrate oxidation in response to re-feeding mice Chow diet,
with the highest flexibility in the mice subjected to the combined
intervention (Fig. 2C and Table 2).
Targeted Metabolomic Analysis in Skeletal Muscle
To characterize the role of muscle, the major organ of energy
utilization, in the differential modulation of metabolic flexibility by
the treatments, targeted metabolomics analysis in the muscle was
performed in mice re-fed Chow diet (see also Fig. 1). Concentra-
tions of 163 metabolites (Table S1) providing sets of hexoses,
amino acids, sugars, acylcarnitines and phospholipids were
measured using flow injection analysis/thermospray mass spec-
trometry (FIA-MS) with Biocrates AbsoluteIDQTM targeted
metabolomics technology.
Partial least squares-discriminant analysis (PLS-DA) of the data
separated mice into three distinct groups, namely the cHF mice,
the cHF+ROSI mice, and the group of mice fed the diets
containing n-3 LC-PUFA (both cHF+F and the cHF+F+ROSI
mice; Fig. 3A). The first PLS-DA component (X-axis) showed a
strong separation between the mice fed diets containing or not n-3
LC PUFA, while the second PLS-DA component (Y-axis) showed
a separation between the cHF mice and the cHF+ROSI mice. A
loading scatter plot was constructed to determine the variables
(metabolites) discriminating between the groups (Fig. 3B). Con-
cerning the PLS-DA component 1, the most influential metabo-
lites were glycerophospholipids, reflecting a difference in fatty acid
composition of the diets. Most of sphingolipids were associated
with the cHF+F and cHF+F+ROSI mice (Fig. 3B and Fig. S1).
The metabolites having the greatest influence on the separation of
the cHF mice were acylcarnitines and amino acids (Fig. 3B and
Fig. S1).
We generated heat maps of the correlation matrices of all
pairwise correlations of muscle acylcarnitines (Fig. 4). These
metabolites are formed in mitochondria, equilibrate with their
cognate acyl CoAs and provide a detailed signature of mitochon-
drial fatty acid metabolism. Obesity accelerates fatty acid
metabolism with possible accumulation of incomplete oxidation
products, which may exacerbate insulin resistance [37,38,42].
Strong associations between all 14 acylcarnitines reflect complete
b-oxidation of fatty acids, while reciprocal association between
short-chain and long-chain acylcarnitines reflect a metabolic
block, when fatty acids are metabolised only partially [37,42].
Furthermore, acetylcarnitine (C2) can be used as a marker of
acetyl-CoA levels, whereas odd-chain acylcarnitines, namely
propionyl-L-carnitine (C3) and isovalerlycarnitine (C5), are
primarily derived from catabolism of BCAA [37–39]. Our analysis
revealed several hotspots and patterns, which discriminated
between the interventions. The interpretations given above
indicate that n-3 LC PUFA improved efficiency of b-oxidation
(Fig. 4A vs Fig. 4B), while rosiglitazone alone had only a negligible
Figure 1. Overview of experimental setup. Starting at 3 months of age, subgroups of mice were fed either Chow or cHF diets, or subjected to
various interventions (cHF+F, cHF+ROSI, and cHF+F+ROSI diets), which lasted for 8 weeks (A). During week 6 of the experiment, indirect calorimetry
was performed using the ‘diet-switch protocol’ (B). At the end of the experiment, animals were killed either following the diet-switch protocol when
re-fed Chow diet (C), or without any additional manipulations, while offered various cHF-based diets (not shown). White and grey background (B, C),
light and dark phase of the day, respectively. Dotted arrow lines (B), periods of data collection for calculation of the mean values of V02, RER, and
PRCF (see Table 1 and Fig. 2).
doi:10.1371/journal.pone.0043764.g001
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effect (Fig. 4A vs Fig. 4C). The combined intervention resulted in a
strong regulation of the metabolism of BCAA (C3 and C5
hotspots) and specifically unmasked the involvement of the
hydroxylated C4 metabolite (C4-OH; Fig. 4D), i.e., either
hydroxybutyrylcarnitine or malonylcarnitine (Table S1). This
was supported by analysis at the level of individual metabolites,
which revealed that even side-chain (C.10) acylcarnitines, arising
from incomplete mitochondrial b-oxidation [37,42], were signif-
icantly reduced in response to the n-3 LC-PUFA, while they were
not affected by rosiglitazone. Levels of shorter side-chain (C,10)
acylcarnitines did not change, while levels of odd-chain acylcarni-
tines (C3+C5) tended to be decreased by all the interventions.
Together with the heatmap analysis, these results suggest different
mechanisms engaged in the beneficial effects of the single
interventions on insulin sensitivity. Thus, n-3 LC-PUFA amelio-
rate lipid-induced mitochondrial stress [37,42], while the combi-
nation with n-3 LC-PUFA and rosiglitazone probably augments
insulin sensitivity by the modulation of branched-chain amino acid
metabolism [37,38]. Furthermore, C4-OH levels were decreased
by all the interventions (Table S1 and Fig. 5A) and n-3 LC-PUFA,
especially in combination with rosiglitazone, exerted a suppressive
effect on the concentration of free amino acids in the muscle
(Table S1 and Fig. 5B). Glucogenic amino acids, namely glycine
and serine, were more affected than amino acids that are both
glucogenic and ketogenic, like tyrosine (Fig. 5B). These results are
in favour of the synergistic improvement of muscle insulin
sensitivity by the combined intervention (see Discussion).
In accordance with the changes in their plasma levels and
amelioration of obesity-associated low-grade inflammation [32],
the content of most of lysophosphatidylcholines (lysoPCs) were
reduced in response to n-3 LC-PUFA also in the muscle,
specifically lysoPCs with polyunsaturated fatty acids C18:2-,
C20:3-, and C20:4- side chains (Table S1 and Fig. 5C). The
combined intervention tended to exert the most pronounced
effects. Levels of sphingolipids (SM) were hardly regulated, except
for hydroxysphingomyeline C24:1 [SM(OH) C24:1], which was
strongly induced by n-3 LC-PUFA, especially in the combined
intervention, while rosiglitazone alone had the opposite effect
(Table S1 and Fig. 4D).
Gene Expression in Skeletal Muscle
To investigate the effects of the interventions on gene expression
in the skeletal muscle, whole genome microarray analysis was
performed in mice re-fed Chow diet. As the initial step, three
groups were compared, being the cHF+F and cHF+ROSI versus
the control cHF mice. Non-stringent analysis of the results
suggested that both single interventions regulated genes engaged
in various biological processes, with only a partial overlap, and
with a stronger effect of n-3 LC PUFA (Table 3). The stronger
effect of n-3 LC PUFA agrees with the stronger effects observed for
metabolomic data as analyzed by PLS-DA (Fig. 3A).
To examine the most prominent changes, genes with a
significant regulation with an absolute fold change (FC) $1.5
were selected (Table S3). In total, 18 and 12 well annotated genes
were detected when the effects of n-3 LC PUFA (Table S2; 12
genes down-regulated, 6 genes up-regulated in the cHF+F mice),
and rosiglitazone (Table S3; 5 genes down-regulated, 7 genes up-
regulated in the cHF+ROSI mice), respectively, were compared.
All detected genes were unique, and mostly specific for the
different interventions, while their number was very small
compared to the number of genes detectable using the Agilent
oligonucleotide arrays (see Methods).
Table 1. Growth characteristics and plasma parameters.
Chow cHF cHF+F cHF+ROSI cHF+F+ROSI
Body weight (g)
Initial 24.760.8 25.960.5 26.260.5 25.160.3 25.560.4
Final 31.461.0 37.661.1f 34.861.1 37.461.2f 32.360.8a,c
Body weight gain 5.760.5 11.761.3f 8.661.0 12.261.1f 6.860.9a,c
Plasma parameters
cHF-based diets
Triglycerides (mmol/l) 0.7060.05 0.9060.11 0.5560.06 0.5560.04f 0.4660.03a,f
NEFA (mmol/l) 0.5660.06 0.4860.08 0.3060.03f 0.4460.05 0.3360.05f
Glucose (mmol/l) 15.160.6 14.660.4 14.160.3 14.660.6 14.160.4
Insulin (nmol/l) 0.1360.01 0.3860.07f 0.2460.03 0.3060.03 0.1960.05a
Re-fed Chow
Triglycerides (mmol/l) 0.6960.13 0.8460.17 0.6360.06 0.4760.06 0.5660.10
NEFA (mmol/l) 0.3960.11 0.3360.03 0.4660.06 0.3560.04 0.2760.07
Glucose (mmol/l) 18.361.11 15.561.1 13.460.8f 16.260.7 15.260.5f
Insulin (nmol/l) 0.1160.02 0.1560.02 0.1260.03 0.1660.03 0.0960.01
b-HB (mmol/l) 46.067.5 95.4618.1f 68.166.9f 94.3611.1f 35.266.4a,c
n 6 8–10 8–10 8–10 8–10
Three-month-old mice were placed on various diets and killed 8 weeks thereafter. Plasma parameters were followed as described in Methods, either in mice with free
access to various cHF-based diets, or when mice were re-fed Chow (using the diet-switch protocol; see also Fig. 1C). BHB, b-hydroxybutyrate in the animals re-fed Chow.
aSignificantly different from cHF;
bsignificantly different from cHF+F;
csignificantly different from cHF+ROSI;
dsignificantly different from cHF+F+ROSI (ANOVA).
fSignificantly different from Chow (t-test).
doi:10.1371/journal.pone.0043764.t001
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As the second step, we sought to find the genes, which could be
additively/synergistically affected by the combined intervention by
direct comparison of the cHF+F+ROSI versus cHF+ROSI mice.
A higher number of genes was regulated as compared with the
sum of genes regulated by single interventions (Table 3). Focusing
on the most regulated genes using FC $1.5 as a threshold again,
in total 39 well-annotated genes were identified to be differentially
expressed, with most of these showing a lower expression in the
cHF+F+ROSI mice (Table S4). The total number of differentially
expressed genes, as well as the extent of their regulation was still
relatively small (4 genes detected with FC $2.0; Table S4).
Detailed inspection of the expression data (Tables S2, S3, and
S4) uncovered 10 genes, which were highly relevant with respect to
a functional interpretation. Therefore, expression of these genes
was verified using real-time quantitative RT-PCR (qRT-PCR)
analysis across all the dietary groups. In addition, 5 genes, which
were not identified using the microarrays, but could help the
functional interpretation, were also included (for the complete list
of genes, see Tables S5). Since the main focus of the analyses was
on the characterisation of the muscle involvement in the
differential effects of the interventions on metabolic flexibility,
gene expression was evaluated not only in the animals re-fed
Chow diet (see above), but also in mice from a separate
experiment, which were killed when fed the cHF-based diets (see
Methods and Fig. 1).
Several genes involved in carbohydrate metabolism showed
significant changes in expression (Fig. 6A): (i) pyruvate dehydro-
genase kinase 4 (Pdk4), a regulatory enzyme limiting oxidation of
glucose by inhibiting the pyruvate dehydrogenase complex [43],
(ii) fructose-1,6-bisphophatase 2 (Fbp2), a key enzyme of
gluconeogenesis catalyzing the hydrolysis of fructose 1,6-bispho-
sphate to fructose 6-phosphate and inorganic phosphate [44], and
(iii) glucose transporter 4 (Glut4), which is essential for the insulin-
stimulated glucose uptake in muscle cells [45]. Changes in Pdk4
expression suggested improved metabolic flexibility in response to
all the interventions, as demonstrated by the down-regulation of
Figure 2. Indirect calorimetry. During week 6 of the experiment, in mice fed cHF diet, or mice subjected to various interventions (cHF+F,
cHF+ROSI, and cHF+F+ROSI diets; n+5; mice randomly chosen from each subgroup, see Table 1), indirect calorimetry was performed using the diet-
switch protocol (Fig. 1B). Thus, during the first part of the measurements (between 6.00 p.m. and 8.00 a.m.), animals had ad libitum access to water
and various cHF-based diets. After that period, the diets were removed and the animals fasted for 10 hours (between 8.00 a.m. and 6.00 p.m.). At the
beginning of the dark phase of the day cycle (at 6.00 p.m.), all the subgroups were offered Chow diet and the measurements continued for 20 more
hours. A and B. Oxygen consumption (A) and RER values (B) during re-feeding Chow diet (mean values). C. Plots of PRCF of RER values during the
periods of fasting (broken lines; data collected between 9.00 a.m. and 5.00 p.m.) and re-feeding Chow (solid lines; data collected between 0.00 p.m.
and 8.00 a.m.). Each curve represents the data pooled from all mice within a given group (n= 5; see above;,1,200 RER measurements per curve). For
the means over different periods of the measurements and for the statistical analysis of these data, see Table 2.
doi:10.1371/journal.pone.0043764.g002
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this gene in mice re-fed Chow diet (Fig. 6A), and they were verified
using Western blot analysis (Fig. 7). In the case of Fbp2, only the
rosiglitazone-based interventions could improved the flexibility, as
revealed by the pronounced down-regulation of this gene in the
mice re-fed Chow diet (Fig. 6A). Only in the case of Glut4, the
combined intervention tended to increase the expression,
independent on the actual feeding status (Fig. 6A).
Lipid metabolism was clearly regulated as well; genes encoding
(i) acyl-CoA thioesterase 1 (Acot1), a mitochondrial enzyme
hydrolyzing medium- and long-chain acyl-CoAs to the free fatty
acid and CoASH [46], (ii) carnitine palmitoyltransferase 1b
(muscle form; Cpt1b), the rate-limiting transporter of activated
fatty acids for mitochondrial b-oxidation in the muscle [47], and
(iii) CD36 protein (Cd36), acting as a plasma membrane, TZD-
inducible fatty acid transporter [48], were all regulated by the
interventions (Fig. 6B). Both Acot1 and Cpt1b showed a relatively
strong response, while especially changes in Cpt1b expression
suggested additive improvement of metabolic flexibility in
response to the combined intervention. In contrast to the strong
regulation of Cpt1b (Fig. 6B), expression of the liver isoform of the
enzyme (Cpt1a) was not affected (Tables S5).
Furthermore, important changes were found in the expression
of genes marking slow (oxidative) muscle fibres [49,50], especially
(i) myosin heavy polypeptides, Myh6 andMyh7, and (ii) troponin
C 1 (Tnnc1; Fig. 6C). In the mice killed when fed the cHF-based
diets, increased expression was observed for all these genes,
suggesting additive/synergistic induction of the oxidative fibers,
while in the mice re-fed Chow diet, expression of these genes was
mostly down-regulated (Myh6 and Myh7), with Tnnc1 showing the
strongest response to the combined intervention (Fig. 6C). The
gene encoding peroxisome proliferator-activated receptor c
coactivator 1a, (Pgc1a), which stimulates the conversion of
muscle fiber type towards oxidative type [51,52], was regulated
by rosiglitazone but not by n-3 LC PUFA (Fig. 6D).
Finally, among other genes showing a strong regulation, genes
encoding enzymes involved in the production of lipid mediators
from various PUFA [53], including a member of the cytochrome
P450 family genes (Cyp1a1; Fig. 6E), were identified. In both
cases, combined intervention resulted in the strongest induction,
independent of the actual feeding status.
Discussion
Indirect calorimetry performed in this study proved an additive
improvement in metabolic flexibility in response to the combined
use of n-3 LC-PUFA and rosiglitazone in mice fed an obesogenic
high-fat diet. These results are in agreement with the changes of
plasma metabolite levels during the fasted to re-fed transition, as
well as with the synergistic improvement of muscle insulin
sensitivity by the combined intervention in these animals
[14,32]. The beneficial effect on metabolic flexibility was observed
during a switch from lipid to carbohydrate fuel. As reported
recently by the group of Blaak, ‘‘the ability to switch from fat
oxidation to carbohydrate oxidation after a meal is already
impaired in the prediabetic state, suggesting this may be an early
factor in the development toward type 2 diabetes’’ [54].
Interestingly, in our animals with ad libitum access to high-fat diet,
no differences between the treatments in fuel partitioning were
found, also in accordance with the lack of correlation between
fasting RER and insulin sensitivity in some human studies
(reviewed in [36]).
It is not known whether the effect of the combined intervention
on metabolic flexibility merely reflects the reduced accumulation
of body fat, when rosiglitazone is administered at a relatively low
dose in the combination with n-3 LC-PUFA (see also [14,32]), or
whether it depends on direct effects on muscle metabolism.
However, several pieces of evidence are in favor of the latter
possibility. Thus, (i) in agreement with a previous study in rats
[55], cHF+F diet, but not cHF+ROSI diet, increased RER values
in mice re-fed Chow, in spite of the absence of an effect on body
weight by neither of the single intervention; (ii) both metabolomic
and gene expression analyses in the muscle documented several
body weight-independent changes induced by the interventions
(see below); and (iii) dietary supplementation with n-3 LC-PUFA,
either in combination with rosiglitazone [14,32] or pioglitazone
[32] resulted in a synergistic induction of adiponectin, while
elevated adiponectin levels were found to be associated with
enhanced metabolic flexibility [56].
Metabolic Profiling in the Muscle
Targeted metabolomic analysis in the muscle revealed relatively
subtle differences between the interventions. This could be
explained by the fact that the set of the measured metabolites
lacked specific markers of carbohydrate metabolism, the process
affected the most during the fasted to re-fed transition. Neverthe-
less, the levels of glucogenic amino acids were regulated as
expected, with the strongest response induced by the combined
intervention. Changes in the regulation and levels of acylcarnitines
suggested distinct and complementary effects of n-3 LC-PUFA and
rosiglitazone, with n-3 LC PUFA supporting mitochondrial b-
oxidation (see [37,38,42]), and the combined intervention
augmenting insulin sensitivity by the modulation of BCAA
metabolism (see [37,38]). In fact, in a previous study [57], the
insulin-senzitizing potency of TZDs was shown to correlate with
modulation of BCAA metabolism in WAT, with the impact on
BCAA levels and insulin sensitivity in the muscle (see [39]). All the
Table 2. Indirect calorimetry.
cHF cHF+F cHF+ROSI cHF+F+ROSI
VO2 (ml/min)
Original diets 2.0060.04 1.9960.09 1.9760.04 1.9760.06
Fasting 1.8360.06 1.8360.03 1.9460.08 1.6960.04b
Re-feeding Chow 1.8560.06 1.9060.06 1.8660.06 1.8160.04
RER
Original diets 0.8460.01 0.8460.01 0.8360.01 0.8760.01
Fasting 0.8060.01 0.8060.01 0.8060.01 0.8160.01
Re-feeding Chow 0.8560.03 0.8960.02 0.8460.02 0.9460.02ab
DRER 0.0560.02 0.0860.01 0.0460.01 0.1260.01ab
At 6 weeks after the initiation of the experiment, oxygen consumption (VO2)
and carbon dioxide production were recorded every 2 min using indirect
calorimetry. The measurements were performed following the diet-switch
protocol in individual mice (Fig. 1B). During the first part of the measurements
(between 6.00 p.m. and 8.00 a.m.), animals had ad libitum access to water and
various cHF-based diets. After that period, the animals were fasted for 10 hours.
At the beginning of the dark cycle at 6.00 p.m., all subgroups were switched to
Chow diet, and the measurements continued for 20 more hours (‘Re-feeding
Chow ‘). The measurements were performed under the 12-hour light-dark cycle
(lights on from 6:00 a.m.) at ambient temperature of 22uC. Data are means6SE
(n= 5; mice randomly chosen from each subgroup, see Table 1) expressed for
the following three time-periods (i) from 0.00 p.m. to 8.00 a.m., feeding various
cHF-based diets; (ii) from 9.00 a.m. to 5 p.m., fasting; and (iii) from 0.00 p.m. to
8.00 a.m., re-feeding Chow. DRER, the difference in RER between mice re-fed
Chow diet and fasted mice.
aSignificantly different from cHF diet;
bsignificantly different from cHF+ROSI diet (ANOVA).
doi:10.1371/journal.pone.0043764.t002
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Figure 3. The effects of various interventions on gastrocnemius muscle metabolome. At 3 month of age, subgroups of mice were fed cHF
diet, or subjected to various interventions using cHF-based diets (cHF+F, cHF+ROSI, and cHF+F+ROSI). Animals were killed while re-fed Chow diet (see
the diet-switch protocol and Fig. 1). Targeted metabolomics analysis was performed in gastrocnemius muscle extracts. In total, concentrations of 163
metabolites were determined using FIA-MS with the Biocrates AbsoluteIDQTM technology (see Table S1) and PLS-DA was performed. A. 2D-score
scatter plot of the first (X-axis) and the second (Y-axis) PLS-DA component are shown for selected groups of mice (n= 7–8; mice randomly chosen
from each subgroup, see Table 1). Mice were fed cHF (black circles), cHF+ROSI (green circles), cHF+F (blue circles), or cHF+F+ROSI (violet circles) diets.
B. Corresponding loading scatter plot. Acylcarnitines (green triangle), amino acids (inverted blue triangle), glycerophospholipids (yellow circles),
sphingolipids (violet circles) and sum of hexoses (red diamante) are shown. The score (A) and loading (B) plots complement each other. The position
of objects (muscle sample) in a given direction in the score plot is determined by variables (metabolites) lying in same direction in the loading plot.
For identification of the individual metabolites shown in B, see Fig. S1.
doi:10.1371/journal.pone.0043764.g003
Figure 4. Heatmap analysis of the effects of various interventions on selected analytes in the muscle. Analysis was performed in mice
re-fed Chow diet (see Fig. 1 and Fig. 3). Heatmap representations of the pairwise correlation matrix were generated using selected muscle
metabolites in mice fed cHF (A), cHF+F (B), cHF+ROSI (C), and cHF+F+ROSI (D) diets. Each square represents Pearson correlation coefficient between
the metabolite in the row with that in the column. The strength of correlation (red, positive; green, negative) is expressed as a color intensity, see the
color scale bar. CX, acylcarnitine with the chain of X carbons; SHORT, sum of acylcarnitines C3-C7; MEDIUM, sum of carnitines C8-C13; LONG, sum of
acylcarnitines C14–18; TOTAL, sum of all acylcarnitines.
doi:10.1371/journal.pone.0043764.g004
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treatments decreased C4-OH, while its regulation with respect to
the levels of other metabolites emerged as a unique marker of the
effect of the combined intervention on muscle metabolome. This
analyte could be either hydroxybutyrylcarnitine or malonylcarni-
tine, reflecting either the muscle levels of b-hydroxybutyrate and
b-hydroxybutyryl-CoA [58], or a-hydroxybutyrate and a-hydro-
xybutyryl-CoA [59], or malonyl-CoA. All these metabolites could
support muscle insulin sensitivity [14,32] since (i) muscle b-
hydroxybutyrate represents a strong marker and a possible causal
factor for insulin resistance, which correlates with plasma NEFA
levels [59]; (ii) a-hydroxybutyrate, a marker of mitochondrial
redox status, is linked to the regulation of BCAA [59] and it was
recently identified as an early biomarker of insulin resistance [60];
and (iii) malonyl-CoA is the key lipogenic intermediate controlling
mitochondrial activity of b-oxidation by inhibiting CPT-1 (ref.
[47]; see below).
Importantly, only the combined intervention could suppress
plasma levels of b-hydroxybutyrate in mice re-fed Chow diet. In
contrast, in the animals with ad libitum access to the cHF-based
diets, or in fasted mice, no difference in the levels of b-
hydroxybutyrate between was observed the interventions [32].
Formation of b-hydroxybutyrate occurs in the liver, as a by-
product of b-oxidation when carbohydrates are scarce. Therefore,
the marked suppression of the plasma b-hydroxybutyrate levels by
the combined intervention suggests that, in addition to the
beneficial muscle metabolic flexibility, also the adaptability of
hepatic metabolism is synergistically improved. That this effect
only occurred in the animals that switched to carbohydrate fuels
supported the improvement in hepatic insulin sensitivity.
Chronic inflammation in obesity triggers insulin resistance [61],
depending also on macrophage accumulation in the muscle and
inflammatory state of muscle cells [62]. Therefore, we sought to
detect changes in muscle metabolome, which could document
anti-inflammatory effects of the treatments. Indeed, levels of
several lysoPCs were decreased by the interventions, and the
combined intervention tended to exert the strongest effect, in
accordance with the notion that lysoPCs are associated with
obesity-induced low-grade systemic inflammation (reviewed in
[32]), and that phospholipase A2-derived lysoPC exert adverse
effects on insulin responsiveness of myocytes [63].
Figure 5. Concentrations of selected metabolites in gastrocnemius muscle extracts. Analysis was performed in mice re-fed Chow diet (see
Fig. 3 and Table 1). A. Carnitines: propionyl-L-carnitine and isovalerlycarnitine (C3+C5); malonyl-L-carnitine (C4-OH); and various even-chain
monounsaturated acylcarnitines (C10:1, C14:1, C16:1, and C18:1; individual acylcarnitines are denoted by their side chain; see Table S1). B. Amino
acids. C. Lysophosphatidylcholines: stearoyl lysophasphatidylcholine (lysoPC C18:0); linoleoyl lysophosphatidylcholine (lysoPC C18:2); and
arachidonoyl lysophasphatidylcholine (lysoPC C20:4). D. Sphingolipids: palmitoyl sphingomyeline (SM C16:0); stearoyl sphingomyeline (SM C18:0);
and hydroxysphingomyeline [SM(OH) C24:1]. D. Data are means6SE (n=7–8). Dietary groups are: cHF (black bars), cHF+F (blue bars); cHF+ROSI
(green bars) and cHF+F+ROSI (violet bars). aSignificantly different from cHF; bsignificantly different from cHF+F; csignificantly different from cHF+ROSI
(ANOVA).
doi:10.1371/journal.pone.0043764.g005
Table 3. Differentially expressed, unique genes classified in biological processes.
Upregulated Downregulated Total
Single interventions cHF+F cHF+ROSI cHF+F cHF+ROSI cHF+F cHF+ROSI
Immune response 17 1 24 4 41 5
Development 15 5 12 2 27 7
G-protein signaling 9 0 13 0 22 0
Angiogenesis 11 4 10 8 21 12
Cell cycle 3 3 15 7 18 10
Transport 4 0 4 0 8 0
Total: 27 7 42 15 69 22
Combined intervention Upregulated Downregulated Total
Development 29 21 50
Muscle contraction 8 18 26
Apoptosis and survival 10 7 17
Cell adhesion 2 12 14
Angiogenesis 5 9 14
Immune response 4 10 14
Transcription 6 7 13
G protein signaling 5 7 12
Regulation of lipid metabolism 3 7 10
Trafficking 5 1 6
Total: 77 99 176
Single interventions, unique genes with absolute FC $1.2 significantly different from cHF; combined intervention, unique genes with absolute FC $1.2 significantly
different from cHF+F (t-test). Genes were manually classified in biological processes using scientific literature and bioinformatical resources, following initial MetaCore
pathway analysis.
doi:10.1371/journal.pone.0043764.t003
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Figure 6. Expression of selected genes in gastrocnemius muscle. Mice were killed either without any additional manipulations, that is, while
offered various ‘original’ cHF-based diets (OrD; crossed bars), or following the diet-switch protocol when re-fed Chow diet (full bars); see Fig. 1.
A.Genes involved in carbohydrate metabolism: pyruvate dehydrogenase kinase isozyme 4 (Pdk4); fructose-1,6-bisphosphatase isoenzyme 2 (Fbp2);
and glucose transporter type 4 (Glut4). B. Genes involved in lipid metabolism: acyl-CoA thioesterase 1 (Acot1); carnitine palmitoyltransferase 1b
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Interestingly, we have found here a specific pattern of regulation
of SM(OH) C24:1 levels in the muscle, with the opposite effects by
the single interventions, while combined intervention strongly
increased the levels of this metabolite. As we have found before,
SM(OH) C24:1 represents the most strongly associated single
metabolite with a genetic variant of serine-palmitoyltransferase
[64], the rate-limiting enzyme in the synthesis of ceramides and
sphingomyelins. Activity of this enzyme is increased in response to
the treatments, which enhances insulin sensitivity, like aerobic
training [65] or pioglitazone [66]. Moreover, the involvement of
ceramide-derived sphingosines in the activation of AMP-activated
protein kinase by adiponectin, downstream from the adiponectin
receptors, was recently suggested [67]. This mechanism, which
should operate in the muscle, suggests a new role for the
sphingolipid metabolism [66] with respect to its long-disputed
role in affecting muscle insulin sensitivity [65,66,68–70]. Our
results further support the importance of SM(OH) C24:1 as a
marker of the muscle sphingosines metabolism.
Gene Expression in the Muscle
Expression profiling in the muscle indicated a higher number of
genes regulated in response to the combined intervention as
compared with any of the single interventions, suggesting multiple
mechanisms of action. Identification of the key metabolic genes
was enabled by the quantitative comparison of the expression
under the different metabolic states, i.e. in the animals relying
mostly on either carbohydrate (mice re-fed Chow) or lipid fuels
(mice with ad libitum access to the cHF-based diets). This approach
revealed the involvement of both glycolysis and fatty acid
oxidation in the preservation of the adaptability of muscle
metabolism (see also ref. [71]); and moreover, it identified several
candidates, namely Pdk4, Fbp2 and Cpt1b, which could be involved
in the additive effects of the combined intervention. That Cpt1b
but not Cpt1a was regulated substantiates the view that Cpt1b was
important for the modulation of fuel partitioning and b-oxidation
by all the interventions, since it is primarily Cpt1b which is more
sensitive to the inhibition by malonyl-CoA [47]. Previous studies
suggested that oxidative (slow) muscle fibers could be important for
metabolic flexibility [36,49]. As compared with the glycolytic
fibers, the oxidative fibers contain more mitochondria [72] and
they are more insulin sensitive and more abundant in the muscle
of insulin-sensitive than insulin-resistant human subjects [68].
Indeed, our unbiased analysis uncovered that several oxidative
fibers genes, namely Myh6, Myh7, and Tnnc1 were regulated in
(Cpt1b); and CD36 antigen (Cd36). C. Slow muscle (oxidative) fiber genes: myosin, heavy polypeptide 6 (Myh6); myosin, heavy polypeptide 7 (Myh7);
and troponin C type 1 (Tnnc1). D. Pgc1a. E. Cytochrome P450, family 1, subfamily a, polypeptide 1 (Cyp1a1). Data are means6SE (n= 7–8). See also
Table S6. aSignificantly different from cHF, OrD; bsignificantly different from cHF+F, OrD; csignificantly different from cHF+ROSI, OrD; dsignificantly
different from cHF+F+ROSI, OrD; esignificantly different from cHF+F+ROSI, re-fed Chow (ANOVA).
doi:10.1371/journal.pone.0043764.g006
Figure 7. Content of PDK4 protein in gastrocnemius muscle. Mice were killed either without any additional manipulations, that is, while
offered the ‘original’ cHF-based diet in fed state (crossed bars), or following the diet-switch protocol when re-fed Chow diet (full bars). A.
Representative Western blot analysis. B. Quantification of PDK4 protein in skeletal muscle. Values are means6S.E. (n= 5–8). aSignificantly different
from mice offered the cHF+F+ROSI diet (ANOVA).
doi:10.1371/journal.pone.0043764.g007
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accordance with their involvement in metabolic flexibility. Our
results suggest that the combined intervention potentiated the
switch between the oxidative and glycolytic fibres, which is
activated in response to the change of metabolic fuels. Thus, the
combined intervention exhibited the most pronounced regulation
of the oxidative fibres genes, while inducing their highest
expression when the animals had ad libitum access to the cHF-
based diets, and the lowest expression in the animals re-fed Chow.
Interestingly, expression of Pgc1a, the master regulator of
mitochondrial biogenesis and the marker of the slow muscle fibers
[51,52], matched the changes in the expression of the oxidative
fibres genes only to a limited extent.
With respects to the anti-inflammatory effects of the interven-
tions, meaningful changes in the expression of Cyp1a1 were found,
showing additive induction by the combination treatment. This
gene is inducible by both TZDs [73], and PUFA [74], acts both as
epoxygenase and hydroxylase, while producing PUFA-derived
lipid mediators, with EPA-derived lipid mediators exerting
presumably anti-inflammatory effects [53].
Conclusions
Our results indicate that the combined use n-3 LC-PUFA and
rosiglitazone preserve metabolic flexibility of mice fed an
obesogenic high-fat diet, with a stronger, additive, effect as
compared with any of the interventions applied individually
(Fig. 8). Indirect calorimetry demonstrated that especially meta-
bolic flexibility to carbohydrates was preserved in response to the
combined intervention, also in agreement with the previously
observed synergistic improvement of muscle insulin sensitivity
under these conditions. Metabolomic and gene expression analyses
suggested that both carbohydrate and lipid metabolism contribute
to a better adaptability to fluctuating metabolic fuels and they
highlighted the importance of mitochondrial fatty acid oxidation
in the adaptability of muscle metabolism, while modulation of
BCAA metabolism may be essential for the beneficial effect of the
combined intervention on muscle insulin sensitivity. Our results
further support the idea that dietary supplementation using n-3
LC-PUFA could improve the efficacy of TZDs, as well as other
insulin-sensitizing and hypolipidemic pharmaceuticals used for the
treatment of obese and type 2 diabetic patients.
Methods
Animals and Treatments
Male C57BL/6N mice (Charles River Laboratories, Sulzfeld,
Germany) were maintained at 22uC on 12-h light-dark cycle (light
from 6.00 a.m.) with free access to water and Chow diet (extruded
Ssniff R/M-H diet; Ssniff Spezialdieten GmbH, Soest, Germany;
with lipid, carbohydrate, and protein content ,3.4, 55.3, and
19.3% wt/wt, respectively; energy density, 16.3 kJ/g). As
described before [14,32], three-month-old mice (Fig. 1) were
randomly assigned (2 animals per cage) to cHF diet (lipid content
,35% wt/wt, mainly corn oil; and carbohydrate, and protein
content ,35.4, and 20.5% wt/wt, respectively) or to the following
‘interventions’ using isocaloric cHF-based diets (energy density,
22.8 kJ/g), namely (i) cHF+F, cHF diet supplemented with n-3
LC-PUFA concentrate (46% DHA, 14% EPA, wt/wt, as
triglycerides; product EPAX 1050 TG; EPAX a.s., Aalesund,
Norway), which replaced 15% wt/wt of dietary lipids; (ii)
cHF+ROSI, cHF diet supplemented with 10 mg rosiglitazone/
kg diet (Avandia; GlaxoSmithKline, USA); and (iii) cHF+F+ROSI,
cHF diet supplemented with both n-3 LC-PUFA concentrate and
rosiglitazone. Chow diet-fed control mice were also included in the
study. During the experiment lasting for 8 weeks (week 1– week 8),
fresh ration of food was distributed daily and food consumption
and body weights were recorded once a week. For the detailed
fatty acid composition of lipids of all the diets, see [14].
Animals were killed by cervical dislocation under pentobarbital
anesthesia (between 9.00 a.m. and 11.00 a.m.), (i) either when
allowed free access to different cHF-based diets (n=8), or (ii) using
a ‘diet-switch protocol’ (Fig. 1) when the animals were first fasted
for 10 hours during the light phase of the day (between 8.00 a.m.
and 6.00 p.m.), than re-fed Chow (starting at 6.00 p.m.), and killed
the following day (n=10). In the second case, glycemia was
evaluated and EDTA-plasma for measurement of various metab-
olites (see below) was collected in fed state, at 7.00 a.m., either
before the initiation of the fasting period (when fed various cHF-
based diets), or before the killing (when re-fed Chow; Fig. 1). In
both cases, gastrocnemius muscle was dissected for RNA analysis
(see below).
The animal experiments were specifically approved by the
Animal Care and Use Committee of the Institute of Physiology
Academy of Sciences of the Czech Republic v.v.i. (Approval
Number: 172/2009) and conducted under the guidelines.
Indirect Calorimetry
To evaluate energy expenditure, as well as metabolic flexibility
to the high-carbohydrate meal, indirect calorimetry was per-
formed using system INCA (Somedic, Horby, Sweden) [19,41]
during week 6 of the experiment (Fig. 1) in singly caged mice
(Eurostandard type II mouse plastic cages, , 6,000 ml; Techni-
plast, Milan, Italy), which were placed in sealed measuring
chambers equipped with thermostatically controlled heat exchang-
ers at 22uC. VO2 and VCO2 were recorded every 2 min under a
constant airflow rate (1000 ml/min). The diet-switch protocol (see
above and Fig. 1) was used, allowing for the evaluation of
metabolic flexibility, which was assessed as the induction in RER
in response to the re-feeding Chow diet, following the period of
fasting. Alternatively, to assess the change in fuel partitioning more
accurately, PRCF curves were constructed based on RER values
pooled from all animals within a given dietary group during the
specific period of the measurement. Provided that PRCF curves
represent the normally distributed data, the values of log EC50 of
PRCF (50th percentile value) correspond to RER values [41].
Metabolite Quantification
NEFA, triglycerides, and b-hydroxybutyrate in EDTA-plasma
and glycemia were assessed as before [32]. In addition, targeted
metabolomics analysis was performed using extracts [75] from
skeletal muscle (100 mg aliquots; samples collected in our previous
study [32]) to determine concentrations of 163 metabolites using a
targeted metabolomics kit (AbsoluteIDQTM kit p150, Biocrates
Life Sciences AG, Innsbruck, Austria) based on FIA-MS as before
[32,64]. Concentrations of all analyzed metabolites are reported in
mM. For the general information on biological roles of the
metabolites, see [64]. In short, 14 amino acids, sum of hexoses,
free carnitine, 26 acylcarnitines, 14 hydroxy- and dicarboxy-
acylcarnitines, 10 sphingomyelins, 5 hydroxysphingomyelins, 38
diacyl-phosphatidylcholines, 39 acyl-alkyl-phospatidylcholines,
and 15 lysophosphatidylcholines were quantified. For the full list
of the measured metabolites and the abbreviations to denote them,
see Table S1.
Gene Expression in Skeletal Muscle
Total RNA was isolated from gastrocnemius muscle samples
stored in RNAlater (Ambion, Austin, TX, USA) at 220uC using
TRI Reagent (Sigma-Aldrich, St. Louis, MO, USA) according to
the manufacturer’s instruction. After extraction, RNA was purified
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by using RNeasy columns (Qiagen, Venlo, The Netherlands).
RNA concentration and purity were measured using the
NanoDrop spectrophotometer (IsoGen Life Science, Maarsen,
The Netherlands). The integrity of RNA was checked with
Experion automated electrophoresis system (BioRad, Veenendaal,
The Netherlands). Levels of selected gene transcripts in total
muscle RNA from individual mice were evaluated using real-time
qRT-PCR [13] and appropriate primers (see Table S5).
Muscle total RNA isolated from individual mice was also
analyzed using Agilent whole genome 44K mouse gene expression
arrays (Agilent Technologies, Inc., Santa Clara, CA, USA),
similarly as described before (ref. [76]; see Supporting Information
S1). The arrays contain 43,379 probes (excluding controls).
Differential gene expression was assessed in two subsequent
microarray analyses using a reference pool design. In the first
analysis mice (n=7–8) of the cHF, cHF+F, and cHF+ROSI
treatment groups were assessed and in the second analysis, the
cHF+ROSI and cHF+F+ROSI were assessed. In total, after
removing probes that were below two times the background,
20,721 probes remained in the first study and 25,922 probes in the
second study. Quality control and data handling was done as
described [76]. More detailed information, including data analysis,
is provided in Supporting Information S1. The gene expression
studies are deposited in Gene Expression Omnibus of NCBI with
GEO accession number GSE36718.
Western Blot Analysis of Protein Levels of PDK4
Frozen muscles (50 mg) were homogenized in 0.3 ml of ice-cold
lysis buffer (20 mmol/l Tris, pH 7.4; 1 mmol/l EDTA; 1%
deoxycholate; 1% Triton X-100; 1 mmol/l phenylmethylsulfonyl
fluoride; 10 mg/ml aprotinin; 10 mg/ml leupeptin and Phospha-
tase-Inhibitor-Mix I [Serva, Heidelberg, Germany]). Tissue lysates
were centrifuged at 15,000 g for 10 minutes at 4uC. Protein
concentration in supernatant was determined by bicinchoninic
acid assay. 50 mg protein was separated by 10% sodium
dodecylsulphate-polyacrylamide gel electrophoresis and trans-
ferred to Immobilon-FL membranes (Millipore, Billerica, MA,
USA). The membranes were then probed with rabbit antibodies
against PDK4 (1:200; Abgent, San Diego, CA, USA). Secondary
antibody conjugated to IRDye 800CW (Li-COR, Lincoln, NE,
USA) was used for detection. Membranes were scanned using an
Odyssey IR scanner (LI-COR). The results were quantified using
AIDA image analysis software (Raytest, Straubenhardt, Germany).
Figure 8. Synopsis of the results of metabolomic and gene expression analyses in the muscle. Metabolomic and gene expression
analyses suggested complementary effects of the single interventions, with rosiglitazone augmenting insulin sensitivity by the modulation of
branched-chain amino acid metabolism, especially when combined with n-3 LC-PUFA (1), and n-3 LC-PUFA supporting specifically complete
oxidation of fatty acids in mitochondria (7). These beneficial metabolic effects were associated with inhibition of low grade tissue inflammation (5)
and the activation of the switch between glycolytic and oxidative muscle fibers (8), especially in the combined intervention. Moreover, rosiglitazone
inhibited gene expression of fructose-1,6-bisphosphatase 2 - a key enzyme of gluconeogenesis (2), while the concentrations of most of
lysophosphatidylcholines were reduced in response to n-3 LC-PUFA (4). Glucogenic amino acids, namely glycine and serine, were affected by the
combined intervention (6). As we published previously [14], the combined intervention also exerted synergistic stimulatory effect on muscle
glycogen synthesis (3). Altered metabolites (bold font) and altered transcripts (bold font, rectangle) are marked. BCAA, branched-chain amino acids;
C, acylcarnitine; CPT1b, carnitine palmitoyltransferase 1b; CYP1a1, member of the cytochrome P450 family genes; FBP2, fructose-1,6-bisphosphatase
2; GLUT4, glucose transporter 4; lysoPCs, lysophosphatidylcholines; PD, pyruvate dehydrogenase; PDK4 pyruvate dehydrogenase kinase 4; PFK,
phosphofructokinase; MYH6 and MYH7, myosin heavy polypeptide; TCA cycle, tricarboxylic acid cycle; TNNC1, troponin C1.
doi:10.1371/journal.pone.0043764.g008
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Statistical Analysis
Growth characteristics, plasma parameters, indirect calorimetry
data, and metabolite concentration profile data were analyzed using
ANOVA and paired t-test as before [19,32]. All values are presented
as means6SE. Comparisons were judged to be significant at
p#0.05. Correlation matrices were computed using MS Excel.
Gene array data was processed with MetaCore Pathway analysis
software (GeneGo, Carlsbad, CA, USA). PLS-DA was performed
using Umetrics SIMCA-P+12 statistical software (Umetrics AB,
Umea, Sweden) as before [32]. When the PLS-DA score plot
showed significantly separated groups, a loading scatter plot was
constructed to determine the variables influencing their separation.
Supporting Information
Figure S1 The effects of various interventions on
gastrocnemius muscle metabolome - detailed loading
scatter plot. Identification of the metabolites shown in the
simplified loading scatter plot (Fig. 3B). Acylcarnitines (green
triangle), aminoacids (inverted blue triangle), lysophosphatidyl-
cholines (yellow circles), diacyl phosphatidylcholines (orange
circles), acyl-alkyl phosphatidylcholines (red circles), sphingolipids
(violet circles) and sum of hexoses (dark green diamante) are
shown. Individual metabolites are indicated by unique numbers
(see Table S1 for the name of each metabolite).
(EPS)
Table S1 List of all 163 metabolites measured in
skeletal muscle extracts - targeted metabolomics anal-
ysis. In short, 14 amino acids, sum of hexoses (H1), free carnitine
(C0), 26 acylcarnitines (C2, C3,…C18:2), 14 hydroxy- and
dicarboxy-acylcarnitines (C-3OH, C4-OH, C5-DC,…C18:1-
OH), 10 sphingomyelins (SM C16:0, SM C16:1,… SM C26:1),
5 hydroxysphingomyelins [SM(OH)C14:1… SM(OH)C24:1], 38
diacyl-phosphatidylcholines (PC aa C24:0 …PC aa C42:6), 39
acyl-alkyl-phospatidylcholines (PC ae C30:0… PC ae C44:6), and
15 lyso-phosphatidylcholines (lysoPC a C6:0….lysoPC a C28:1)
were identified in extracts of skeletal muscle from animals
subjected to various interventions and killed when re-fed Chow
(see Methods and Fig. 1). Concentrations of all analysed
metabolites are reported in mM. All metabolites above were
determined using flow injection analysis/thermospray mass
spectrometry (FIA-MS) with Biocrates AbsoluteIDQTM targeted
metabolomics technology. Data are means6SE (n=7–8).
(XLS)
Table S2 Differentially regulated probesets expressed
in cHF+F versus control cHF dietary groups. The data
provided represents only the statistical significant differentially
expressed probesets of the microarrays (cHF: n=8, cHF+F: n=8)
which showed a mean absolute fold change $1.5 (cHF+F/cHF).
(DOC)
Table S3 Differentially regulated probesets expressed
in cHF+ROSI versus cHF dietary groups. The data
provided represents only the statistical significant differentially
expressed probesets of the microarrays (cHF+ROSI: n=8, cHF:
n=8) which showed a mean absolute fold change $1.5
(cHF+ROSI/cHF).
(DOC)
Table S4 Differentially regulated probesets expressed
in cHF+F+ROSI versus cHF+ROSI dietary groups. The
data provided represents only the statistical significant differen-
tially expressed probesets of the microarrays (cHF+F+ROSI: n=8,
cHF+ROSI: n=8) which showed a mean absolute fold change
$1.5 (cHF+F+ROSI/cHF+ROSI).
(DOC)
Table S5 Real-time quantitative RT-PCR analysis:
genes and primers.
(DOC)
Table S6 Real-time quantitative RT-PCR analysis in
skeletal muscle. At the end of the experiment, mice were killed
either without any additional manipulations, that is, while offered
the ‘original’ cHF-based diets (OrD), or following the ‘diet-switch
protocol’ when re-fed Chow diet; see Fig. 1. Control mice
maintained on Chow diet throughout the intervention and killed
in ad libitum fed state were also analyzed. Data are means6SE
(n=7–8). For gene symbols, see Table S5. a Significantly different
from cHF, OrD. b significantly different from cHF+F, OrD.
c significantly different from cHF+ROSI, OrD. d significantly
different from cHF+F+ROSI, OrD. e Significantly different from
cHF, Re-fed Chow. f significantly different from cHF+F, Re-fed
Chow. g significantly different from cHF+ROSI, Re-fed Chow.
h significantly different from cHF+F+ROSI, Re-fed Chow (Two-
way ANOVA). i significantly different from Chow (t-test).
(DOC)
Supporting Information S1
(DOC)
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